365 related articles for article (PubMed ID: 14674720)
1. Dopamine resistance of prolactinomas.
Molitch ME
Pituitary; 2003; 6(1):19-27. PubMed ID: 14674720
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic resistance in prolactinoma patients.
Molitch ME
Pituitary; 2005; 8(1):43-52. PubMed ID: 16411068
[TBL] [Abstract][Full Text] [Related]
3. Management of medically refractory prolactinoma.
Molitch ME
J Neurooncol; 2014 May; 117(3):421-8. PubMed ID: 24146188
[TBL] [Abstract][Full Text] [Related]
4. The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma.
Howell DL; Wasilewski K; Mazewski CM; Hudgins RJ; Meacham LR
J Pediatr Hematol Oncol; 2005 Jun; 27(6):326-9. PubMed ID: 15956887
[TBL] [Abstract][Full Text] [Related]
5. Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine.
Delgrange E; Maiter D; Donckier J
Eur J Endocrinol; 1996 Apr; 134(4):454-6. PubMed ID: 8640297
[TBL] [Abstract][Full Text] [Related]
6. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
7. The assessment of cabergoline efficacy and tolerability in patients with pituitary prolactinoma type.
Bolko P; Jaskuła M; Waśko R; Wołuń M; Sowiński J
Pol Arch Med Wewn; 2003 May; 109(5):489-95. PubMed ID: 14768178
[TBL] [Abstract][Full Text] [Related]
8. Management of Dopamine Agonist-Resistant Prolactinoma.
Maiter D
Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
[TBL] [Abstract][Full Text] [Related]
9. Treatment of pituitary tumors: dopamine agonists.
Iván G; Szigeti-Csúcs N; Oláh M; Nagy GM; Góth MI
Endocrine; 2005 Oct; 28(1):101-10. PubMed ID: 16311416
[TBL] [Abstract][Full Text] [Related]
10. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
[TBL] [Abstract][Full Text] [Related]
11. Dopamine receptor agonists for treating prolactinomas.
Colao A; di Sarno A; Pivonello R; di Somma C; Lombardi G
Expert Opin Investig Drugs; 2002 Jun; 11(6):787-800. PubMed ID: 12036422
[TBL] [Abstract][Full Text] [Related]
12. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
13. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
14. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
15. Secondary Resistance to dopamine agonist after thirteen months of successful treatment in a 42 years old man.
Laboy-Ortiz IE; Velez-Maymí S; Hernán Martínez J; Trinidad R; Mangual M; Sanchez A; Gutierrez M; Mansilla P; Rivera C; Palermo C; de Lourdes Miranda M; Brau R
Bol Asoc Med P R; 2016; 108(1):31-36. PubMed ID: 29193928
[TBL] [Abstract][Full Text] [Related]
16. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
[TBL] [Abstract][Full Text] [Related]
17. Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists.
De Sousa SM; Chapman IM; Falhammar H; Torpy DJ
Endocrine; 2017 Feb; 55(2):618-624. PubMed ID: 27601019
[TBL] [Abstract][Full Text] [Related]
18. Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report.
Kawabata Y; Ueno Y; Horikawa F; Miyake H; Miki N; Ono M
Surg Neurol; 2008 Jan; 69(1):85-8; discussion 88. PubMed ID: 17967478
[TBL] [Abstract][Full Text] [Related]
19. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
20. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma.
Gillam MP; Middler S; Freed DJ; Molitch ME
J Clin Endocrinol Metab; 2002 Oct; 87(10):4447-51. PubMed ID: 12364416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
